嘉应学院医学院附属医院麻醉科,广东,梅州,514031
网络首发:2018-07-19,
纸质出版:2018
移动端阅览
邹志聪, 温婧, 戴龙彬, 等. 布托啡诺逆转ABCB1 蛋白诱导的白血病多重耐药的 效果和机制[J]. 中山大学学报(医学科学版), 2018,39(4).
ZOU Zhi-cong, WEN Jing, DAI Long-bin, et al. Efficiency and Mechanism Sensitizing ABCB1-mediated Multidrug Resistance of Leukemia Cells by Butorphanol as a Synthetic Opioid[J]. Journal of Sun Yat-sen University (Medical Sciences), 2018, 39(4).
邹志聪, 温婧, 戴龙彬, 等. 布托啡诺逆转ABCB1 蛋白诱导的白血病多重耐药的 效果和机制[J]. 中山大学学报(医学科学版), 2018,39(4). DOI:
ZOU Zhi-cong, WEN Jing, DAI Long-bin, et al. Efficiency and Mechanism Sensitizing ABCB1-mediated Multidrug Resistance of Leukemia Cells by Butorphanol as a Synthetic Opioid[J]. Journal of Sun Yat-sen University (Medical Sciences), 2018, 39(4). DOI:
【目的】研究布托啡诺在临床使用剂量范围内通过抑制ABCB1的转运功能增加白血病耐药细胞的化 疗药物敏感性。【方法】采用HL60及其ABCB1过表达的耐药细胞株HL60/VCR、K562及其ABCB1过表达的耐药 细胞株K562/ADR 均在培养环境中加入含胎牛血清的DMEM 或RPMI-1640的培养液中进行培养。采用MTT法 检测布托啡诺的细胞毒性,通过流式细胞仪检测阿霉素(DOX)在HL60/VCR细胞内的累积程度;加入布托啡诺 培养72 h后用免疫荧光观察ABCB1在细胞膜表面的形态和分布变化以及采用Western Blotting检测ABCB1的表达 水平。【结果】布托啡诺能将K562/ADR细胞的阿霉素的抵抗倍数由48.1倍下降到9.6倍,长春新碱(VCR)的抵抗倍 数由108.4倍下降到20.7倍,HL60/VCR的DOX的抵抗倍数由37.8倍下降到7.6倍,长春新碱抵抗倍数由23.4下降 到4.8倍,差异均有统计学意义。ABCB1的表达水平及其在细胞膜上的定位没有变化。【结论】布托啡诺明显降低 阿霉素和长春新碱在ABCB1过表达的白血病耐药细胞株中的IC50,有效增加阿霉素在HL60/VCR细胞内的累积水 平。布托啡诺不改变HL60/VCR和K562/ADR细胞ABCB1的表达水平和ABCB1在细胞膜表面的形态和定位。
【Objective】To explore whether Butorphanol,at a clinically used dose,can increase the chemosensitivity of drug-resistant leukemia cells to conventional anticancer drugs through inhibiting the functions of ABCB1. Therefore, exploring potentially chemotherapeutic sensitizers from previously approved drugs in clinic maybe a more promising approach。【Methods】HL60 cells and their ABCB1- overexpressing cells HL60/VCR,K562 cells and their ABCB1- overexpressing cells K562/ADR were obtained from the Institute of Hematology,the Chinese Academy of Medical Sciences. All the cells were cultured in DMEM and RPMI-1640 with FBS. The cytotoxicity of Butorphanol was determined through MTT assay. The concentration required to inhibit cell growth by 50%(IC50)was calculated from survival curves using the Bliss methods. The resistance-fold was calculated by dividing the IC50 value for the MDR cells with or without inhibitor by that of the parental cells without inhibitor. The intracellular doxorubicin(DOX)accumulation assay were performed by flow cytometry. Western blotting was used to determine the ABCB1 protein levels. Immunofluorescence staining was used to observe cellular membrane locations of ABCB1. Model of molecular docking for Butorphanol binding folds of DOX and VCR from 48.1 to 9.6,108.4 to 20.7 in K562/ADR,respectively. In HL60/VCR,the resistance folds of DOX and VCR were decreased from 37.8 to 7.6,23.4 to 4.8,respectively. Butorphanol did not alter the ABCB1 protein expression levels in the HL60/VCR and K562/ADR cells and their localizations in the plasma membranes of HL60/VCR cells.【Conclusions】Butorphanol decreased the IC50 values and resistance folds of ABCB1 substrates Doxorubicin(DOX) and Vincristine (VCR) in the ABCB1- overexpressing HL60/VCR and K562/ADR cells;Butorphanol dramatically increased the intracellular accumulation levels of Doxorubicin in the HL60/VCR cells. Mechanistic investigations demonstrated that Butorphanol did not alter the protein expression or localization of ABCB1 in HL60/VCR and K562/ADR.
0
浏览量
389
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
